1 MEK-Dependent Negative Feedback

Author Manuscript Published OnlineFirst on December 20, 2013; DOI: 10.1158/2159-8290.CD-13-0235 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.

MEK-Dependent Negative Feedback Underlies BCR-ABL-Mediated Oncogene

Addiction

#,,'$#0 1+311#,SQ*'1 #2& T 1 2#0#TQ* (-,#UQ3 , 1#1V!0'#2-VQ

#-3,%V5--)3,WQ( 007)T 7*-0TQXQYQ *+ (30*',% +#VQ& 0*#1)T0 ')V ,"-#'*!T

)& &SQTQY

*Equal Contribution

1Department of Pharmaceutical Sciences and Pharmacogenomics, University of

California, San Francisco, California 94143 U.S.A.

2Division of Hematology/Oncology, University of California, San Francisco, California

94143 U.S.A.

3Department of Chemistry and Chemical Biology, University of California, San

Francisco, California 94158 U.S.A.

4Department of Pharmaceutical Chemistry, University of California, San Francisco,

California 94158 U.S.A.

5Department of Otolaryngology, University of California, San Francisco, California

94115 U.S.A.

6Department of Epidemiology and Biostatistics, University of California, San Francisco,

California 94158 U.S.A.

7Helen Diller Family Comprehensive Cancer Center, University of California, San

Francisco, California 94143 U.S.A.

.3,,',%'2*#S-#% 2'4#1##" !)1 !'*'2 2#1(.V ( ""'!2'-,

Downloaded from cancerdiscovery.aacrjournals.org on September 30, 2021. © 2013 American Association for Cancer Research. Author Manuscript Published OnlineFirst on December 20, 2013; DOI: 10.1158/2159-8290.CD-13-0235 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.

3#75-0"1S(.V (R-#% 2'4#1##" !)R!&-1.&-.0-2#-+'!1R 3TR ,!-%#,#

""'!2'-,

6 ,31!0'.2--2#1

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

-00#1.-,"',% 32&-0S

-#'*!T)& &Q6T>TQ!&T>T

WSU! 0, 1131 4#,3#6)()SVYS

) ,10 ,!'1!-Q [VSVU

,1& &+#"'!',#T3!1$T#"3

!&-,#SVSWVYXVUURU

1 6SVSWVYXVUYTW

B-0"-3,2SWZYR

120 !2SSVY

Abstract

&#!*','! *#6.#0'#,!#5'2&(.V (270-1',#)', 1#',&' '2-013:1$-02&#

20# 2+#,2-$!&0-,'!+7#*-'"*#3)#+' 6.0-4'"#1!-+.#**',%#4'"#,!#$-0

-,!-%#,# ""'!2'-,T##2Q2&#+-*#!3* 0 1'1-$-,!-%#,# ""'!2'-,0#+ ',1#*31'4#T

&0-3%&3, ' 1#"/3 ,2'2 2'4#.&-1.&-.0-2#-+'! , *71#1-$6!#**120 ,1'#,2*7

#6.-1#"2-(.V (3:Q5#'"#,2'$'#".#01'12#,2"-5,0#%3* 2'-,-$%0-52&$ !2-0

0#!#.2-0<1V.1'%, *',%. 2&5 71TB#2&#,#12 *'1&#" ,"4 *'" 2#" 2'113#V

0#*#4 ,2'1-%#,'!+-"#*-$(.V (V+#"' 2#" ""'!2'-,Q ,"$-3,"#4'"#,!#$-0

+7#*-'"<1V.1'%, *',%. 2&5 70#5'0',%2& 2.0-$-3,"*7 ,".#01'12#,2*7" +.#,1

.&71'-*-%'!. 2&5 7 !2'4 2'-,TB#"#+-,120 2#2& 2#4#,23 *0#12-0 2'-,-$

*'% ,"V+#"' 2#"<1V.. 2&5 7 !2'4 2'-,'1',13$$'!'#,22-$3**70#1!3#!#**1$0-+

!-+.#2',% .-.2-2'!$ 2#T:,!-,20 122-.0#4'-315-0)5'2&(. 1GXRR',

+#* ,-+ !#**1Q$##" !)',&' '2'-,$-**-5',%(.V (3:20# 2+#,2'1+ 0)#"*7

.0-*-,%#"Q#62#,"',% #7-,"2'+#0#/3'0#"2-','2' 2# .-.2-1'1T

6#!& ,'12'! **7Q(.V (V+#"' 2#"-,!-%#,# ""'!2'-,'1$ !'*'2 2#" 7.#01'12#,2

&'%&*#4#*1-$63V"#.#,"#,2,#% 2'4#$##" !)T

Statement of Significance

B#$-3,"2& 2(.V (! ,!-,$#0 ""'!2'-,in vitro 70#5'0',%+7#*-'"%0-52&

$ !2-00#!#.2-01'%, *',%2&0-3% *'1&+#,2-$63V"#.#,"#,2,#% 2'4#

$##" !)T 30$',"',%1.0#"'!22& 2"##.#0Q+-0#"30 *#0#1.-,1#12-2 0%#2#"

%#,21 !0-11 0 ,%#-$+ *'%, ,!'#1+ 7 #$ !'*'2 2#" 7+ ',2 ',',%,#% 2'4#

$##" !)!-,!300#,2*75'2&-,!-.0-2#',',&' '2'-,T

INTRODUCTION

0 ,1* 2'-, *123"'#15'2&1+ **+-*#!3*#270-1',#)', 1#',&' '2-013:1',

. 2'#,215'2&!&0-,'!+7#*-'"*#3)#+' 6& 4#!-,4',!',%*7"#+-,120 2#"2& 2

2&#!*','! * !2'4'27-$2# %#,21'1 !&'#4#"2&0-3%&',&' '2'-,-$2&#',2#,"#"

2 0%#2(.V (ST-" 2#Q2&#&'%&0 2#-$13!!#11 11-!' 2#"5'2&(.V (3:1

.0-4'"#12&#+-12!-+.#**',%!*','! *#4'"#,!#$-02&#.&#,-+#,-,-$b-,!-%#,#

""'!2'-,cQ2&##6/3'1'2#0#*' ,!#-$! ,!#0!#**13.-, . 2&-*-%'! **7 !2'4 2#"

-,!-%#,#T ,!-%#,# ""'!2'-,#, *#12 0%#2#"2� .'#12-#$$#!2!*','! *

0#1.-,1#1 ,"1'+3*2 ,#-31*7! 31#*'22*#2-6'!'27T4#,',2&#+-12 "4 ,!#"

.& 1#1-$6Q 13 12 ,2' *.0-.-02'-,-$. 2'#,21! , !&'#4#"##.0#1.-,1#15'2&

(.V (3:1TT

303,"#012 ,"',%-$2&#+-*#!3* 0 1'1-$-,!-%#,# ""'!2'-,'1.--0T

)& 0+ #2 *.0-.-1#"2#0+b-,!-%#,'!1&-!)c2-"#1!0' #2&##$$#!22& 2

!2'4 2#"-,!-%#,#1& 4#-,2&# * ,!# #25##,.0-1304'4 * ,".0- .-.2-2'!

1'%, *1T&#-,!-%#,'!1&-!)+-"#*.0-.-1#12& 23.-, !32#',&' '2'-,-$

-,!-%#,# !2'4'27Q +-0#0 .'""#! 7',.0-1304'4 *1'%, *1*# "12- 12 2#2& 2

$ 4-01 .-.2-1'1UTB&'*#2&'1+-"#*.0-4'"#1 31#$3*!-,!#.23 *$0 +#5-0)',

5&'!&2- #%',2-3,"#012 ,"2&#.&#,-+#,-,-$-,!-%#,# ""'!2'-,Q#4'"#,!#2-

13..-022&#-,!-%#,'!1&-!)+-"#*'1* 0%#*7!'0!3+12 ,2' *R+-*#!3* 0+#!& ,'1+1

2& 2*# "2-2&#.0-.-1#"&#'%&2#,#"*#4#*1-$.0-1304'4 * ,".0- .-.2-2'!1'%, *1

& 4#,-2 ##,5#**V!& 0 !2#0'8#"T

4#02&#. 12"#! "#Q,3+#0-31-,!-%#,'!)', 1#1', 4 0'#27-$! ,!#01

& 4# ##,'"#,2'$'#" ,"!*','! **72 0%#2#"Q',!*3"',%<1. ," 3',,-,V1+ **

!#***3,%! ,!#0Q(. 1GXRR',+#* ,-+ ,"!-*-0#!2 *! ,!#0Q ,"1UV:>',

!32#+7#*-'"*#3)#+' 6T;-5#4#0Q#$$-0212-#620 .-* 2#2&#!*','! *13!!#11

-$(.V (3:2� .7',62--2�+ *'%, ,!'#1& 4#$ '*#"R2&#+ (-0'27-$

. 2'#,2120# 2#"5'2&-2�!*','! **7 !2'4#3:1"-,-2 !&'#4#0#1.-,1#1-$1'+'* 0

+ %,'23"#T1-0#6 +.*#Q2#*#!2'4#(. 1',&' '2-04#+30 $#,' Q5&'!&'1

..0-4#"$-0(. 1GXRRV.-1'2'4#+#2 12 2'!+#* ,-+ Q0 0#*7#$$#!21"##.

0#"3!2'-,1',23+-04-*3+#VT:,2#0#12',%*7Q63',&' '2-01 0# !2'4#',

(. 1GXRRV#6.0#11',%!#**1in vitro 32Q3,#6.#!2#"*7Q,-2',!#**15'2& !2'4 2#"

0#!#.2-0270-1',#)', 1#1.312& 2 !2'4 2#2&#. ) 63 .3. 2&5 7WT

!0#4'-31123"'#1"#+-,120 2#"2& 2(. 1GXRR#12 *'1 &'%&*#4#*-$.3V

"'0#!2#"20 ,1!0'.2'-, *-32.32 ,"63V"#.#,"#,2,#% 2'4#$##" !)-$%0-52&

$ !2-0V0#!#.2-0<1V.1'%, *',%Q5�# 1 !2'4 2#"-,!-%#,'!.31"-,-2T

""'2'-, **7Q',!-,20 122-.31Q(. 1GXRR#1! .#163V"#.#,"#,2,#% 2'4#

$##" !)XT

:2& 1 ##,.-123* 2#"2& 2#$$'!'#,2 7. 11-$(. 1)', 1#',&' '2'-,2&0-3%&

<1V.V+#"' 2#"0#V !2'4 2'-,-$2&#. ) 6 !31'%, *',%. 2&5 7+ 7 **-5

+#* ,-+ !#**12-1304'4#',2+-0+'!0-#,4'0-,+#,2T.#!#,2#6.#0'+#,2 *

" 2 & 1"#+-,120 2#"2& 2+#* ,-+ Q!-*-0#!2 *Q ,"2&70-'"! ,!#0!#**1

& 0 -0',%(. 1GXRR+32 2'-,1 0#',�#,2*7.0'+#"2-!'0!3+4#,2(. 1

',&' '2'-, 74#+30 $#,' 2&0-3%&0 .'"0#*'#$-$,#% 2'4#$##" !)-$<1V.

1'%, *',%YVSST

;#0#Q5#1-3%&22-!& 0 !2#0'8#2&#+-*#!3* 0+#!& ,'1+12& 23,"#0*'#

(.V (V+#"' 2#"-,!-%#,# ""'!2'-,', ,#$$-022-3,"#012 ,"5& 2+ )#12&'1

)', 1#2&# #12V4 *'" 2#"2 0%#2',&3+ ,! ,!#0TB# ..*'#" ,3, ' 1#")',#2'!

/3 ,2'2 2'4#.&-1.&-.0-2#-+'! , *71'12-6!#**120 ,1'#,2*7#6.-1#"2-2&#

(.V (3:" 1 2',' 2-'"#,2'$7! ,"'" 2#+#"' 2-01-$(.V (V"#.#,"#,2!#**

1304'4 *T-2#122&#'+.-02 ,!#-$2&#- 1#04#"1'%, *',%!& ,%#1Q5##12 *'1&#"

2'113# ,"1.#!'#1V0#*#4 ,2'1-%#,'!+-"#*1712#+2-+-*#!3* 0*7!& 0 !2#0'8#(.V

(V+#"' 2#"-,!-%#,# ""'!2'-, ,"4 *'" 2#"-30$',"',%1',. 2'#,2V"#0'4#"!#**

*',#1T

RESULTS

Phosphoproteomic Analysis of Pulsed Dasatinib-Treated CML Cells

Reveals Durable Alterations in Growth-Factor Signaling Pathways. !0#4'-31

5-0)"#+-,120 2#"2& 220 ,1'#,2#6.-130#TR+',32#1-$6!#***',#12-

!*','! **70#*#4 ,2!-,!#,20 2'-,1-$" 1 2',' #*'!'21 .-.2-1'15'2&)',#2'!11'+'* 0

2-!-,2',3-313:#6.-130#Q"#1.'2##4'"#,!#2& 2(.V ()', 1# !2'4'27'1* 0%#*7

0#12-0#"5'2&',$-30&-301-$"03%5 1&-32STVSVTB#&7.-2'8#"2& 22&#

.&-1.&-07* 2'-,12 231-$ 13 1#2-$.0-2#',1+312 #"30 *7 *2#0#"Q ,"!0'2'! *

+#"' 2-01-$(.V (V+#"' 2#"!#**1304'4 *5-3*" #',!*3"#" +-,%122&'1%0-3.T

B#2�#$-0#3,"#02--) ,3, ' 1#")',#2'!Q/3 ,2'2 2'4# 11#11+#,2-$

.&-1.&-270-1',#V!-,2 ',',%.0-2#',1',2&#6. 2'#,2V"#0'4#"!#***',#Q3WXTQ

20 ,1'#,2*7#6.-1#"2- &'%&V"-1#.3*1#;>!-$SRR,6" 1 2',' 31',%12 *#

'1-2-.#* #*',% 7 +',- !'"1',!3*230#): TB#13!!#11$3**7'"#,2'$'#"SZV

.&-1.&-270-1',#0#1'"3#1',STX"'$$#0#,2.0-2#',1Q0#.0#1#,2',%2&#+-12

!-+.0#&#,1'4#)',#2'! , *71'1-$3:V20# 2#"6. 2'#,2V"#0'4#"!#**12-" 2#

supplemental table 1TB#!-+. 0#"2&#/3 ,2'$'#".&-1.&-270-1',#.0-$'*#

#$-0#3:20# 2+#,2Q $2#0TR+',32#1-$3:#6.-130#Q ," 22&0## ,"1'6&-301

$2#03:5 1&-32figure 1aT

B#%0-3.#".&-1.&-270-1',#.#.2'"#1 1#"-,2&#. 22#0,-$270-1',#

+-"'$'! 2'-,$-**-5',%;>!" 1 2',' 20# 2+#,2T5#,27V$-30270-1',#0#1'"3#1

5#0#20 ,1'#,2*7"#.&-1.&-07* 2#"QUS5#0#%0 "3 **7"#.&-1.&-07* 2#"QVX5#0#

,-2 ..0#!' *7 *2#0#"Q ,"1#4#,5#0#&7.#0.&-1.&-07* 2#"T--2 *7QWW270-1',#

0#1'"3#15#0#.#01'12#,2*7"#.&-1.&-07* 2#"$-**-5',%3:5 1&-32Q ,"$3,!2'-, *

#,0'!&+#,2-$2#.#.2'"#10#4# *#" ,-4#0V0#.0#1#,2 2'-,-$.0-2#',1',4-*4#"

',<1V.1'%, *',%. 2&5 71supplemental table 2T +-,%122#5#0#270-1',#

0#1'"3#1$0-+) W (Q.3S TQ< (S ,");ST!&-1.&-270-1',#.#.2'"#1

11-!' 2#"5'2&!:U3 3. 2&5 7 !2'4 2'-,5#0##'2 ,1'#,2*7

"#.&-1.&-07* 2#"-0,-2 *2#0#"figure 1bT)#4#0 *-$2'%, *',%!& ,%#1

'"#,2'$'#"',2&#.&-1.&-.0-2#-+'! , *71'15#0#!-,$'0+#" 75#12#0,

'++3,- *-2',3WXT!#**1 ,"2&#',"#.#,"#,2. 2'#,2V"#0'4#"6!#***',#37ZSTT

B&'*#270-1',#0#1'"3#15'2&',2&#!:U3 3. 2&5 75#0#,-2"30 *7 *2#0#"',

2&#.&-1.&-.0-2#-+'! , *71'1Q1#0',#.&-1.&-07* 2'-,-$)X)TUW )TUX5 1

"30 *7 *2#0#"', 2'+#V"#.#,"#,2+ ,,#0$-**-5',%3:20# 2+#,2figure 1cT

)'+'* 0.&-1.&-07* 2'-,!& ,%#15#0#- 1#04#"',3WXT ,"37ZST!#**120# 2#"

5'2& ;>!-$2&#(.V (3:'+ 2',' supplemental figure 1Q 0%3',%2& 22&#

- 1#04#"1'%, *',%!& ,%#1 0#*')#*7 !-,1#/3#,!#-$(.V (',&' '2'-,Q ,",-2

2�#13*2-$3,',2#,"#"-$$V2 0%#2)', 1#',&' '2'-,T

*2&-3%&.&-1.&-07* 2'-, 22&#(.V ( !2'4 2'-,*--.1'2##U[UQ5&'!&'1

#11#,2' *$-0)', 1# !2'4'27Q5 1-,*720 ,1'#,2*7 1#,2$-**-5',%;>!" 1 2','

20# 2+#,2Q.&-1.&-.0-2#-+'! ,"5#12#0,'++3,- *-2 , *71#10#4# *#"

13 12 ,2' *4 0' 2'-,',.&-1.&-07* 2'-,!& ,%#1-$(.V (270-1',#0#1'"3#1

figure 1dT-**#!2'4#*7Q-30.&-1.&-.0-2#-+'! ,"'++3,- *-2 , *71#1Q!-3.*#"

5'2&.0#4'-31123"'#1Q13%%#12 0#/3'0#+#,2$-02&#+ ',2#, ,!#-$ 2*# 1225--$

2&0##! ,-,'! *(.V ( !2'4 2#". 2&5 71 3 ) Q. ) 63 .3Q ,"

!:U3$-06!#**1304'4 *in vitroSWT1302�+-0#Q2#- 1#04 2'-,113%%#12

2& 2.#01'12#,2 !2'4 2'-,-$<1V.1'%, *',%. 2&5 71'1!0'2'! *$-0(.V (V

+#"' 2#"-,!-%#,# ""'!2'-,T

BCR-ABL Confers a State of Oncogene Addiction in Human Myeloid Cells

In VitroT-',4#12'% 2#5�(.V ( ..0-.0' 2#1<1V.1'%, *',%. 2&5 712-

#12 *'1&-,!-%#,# ""'!2'-,Q5#1-3%&22-+-"#*-,!-%#,# ""'!2'-,in vitro 7

#12 *'1&',% ,'1-%#,'!!#***',#+-"#*1712#+T;3+ ,V"#0'4#"#072&0-*#3)#+'

1S!#**10#/3'0#&<6V)1-0&:VU$-0.0-*'$#0 2'-, ,"1304'4 *in vitroQ 32! , #

20 ,1$-0+#"2-%0-52&$ !2-0',"#.#,"#,!# 7(.V (SXTB##12 *'1&#".--*1

-$1S .30- ,"1S (.V (!#**12&0-3%&0#20-4'0 *20 ,1"3!2'-,TB#12#0,

'++3,- *-2 , *71'1!-,$'0+#"2&##6.0#11'-,-$.&-1.&-07* 2#"(.V (.0-2#',

',1S (.V (!#**1 ," !2'4 2'-,-$"-5,120# +2 0%#21.3Q) W (Q

.3S T ,")Xsupplemental figure 2a, 2bT

-"#2#0+',#'$1S (.V (!#**1& 4# !/3'0#"0#*' ,!#3.-,(.V (

!2'4'27$-01304'4 * ,"2�# 7203*70#.0#1#,2 +-"#*-$-,!-%#,# ""'!2'-,Q5#

[

+# 130#"2&# +-3,2-$ .-.2-1'1',"3!#"',0#1.-,1#2-1'+3*2 ,#-31%0-52&

$ !2-0"#.0'4 2'-, ,"" 1 2',' 20# 2+#,2T:,1S .30-!#**1&<6V)1V"#.0'4 2'-,

*-,#*#"2-"#!0# 1#"4' '*'27Q ,"" 1 2',' & ",- ""'2'-, *'+. !2-,2&#

#62#,2-$ .-.2-1'1',"3!#"T:,1& 0.!-,20 12Q1S (.V (!#**13,"#05#,2

12 2'12'! **71'%,'$'! ,2',!0# 1#', .-.2-1'15&#,20# 2#"5'2&" 1 2',' figure

2aT6-0#-4#0Q!-,2',3-31!-V20# 2+#,25'2&&<6V)1 ,"" 1 2',' $3**70#1!3#"

1S .30-!#**1$0-+ .-.2-1'1Q5&'*#1S (.V (!#**15#0#-,*7. 02' **7

0#1!3#"$0-+" 1 2',' V+#"' 2#" .-.2-1'1 7&<6V)1T#0#13*21"#+-,120 2#

2& 2(.V (#12 *'1 12 2#-$-,!-%#,# ""'!2'-,',1S!#**1Q5&'!&'1

11-!' 2#"5'2&$3,!2'-, **7 *2#0#"<6V)10#!#.2-0<6V)1.1'%, *',%T6-0#

0- "*7Q2#$',"',%1'+.*'! 2#0#5'0',%-$<1V.1'%, *',%. 2&5 71',2&#

#12 *'1&+#,2-$2&#(.V (V ""'!2#"12 2#T

BCR-ABL Kinase Activity Attenuates GM-CSFR Signal Transduction in

TF1 CellsT-$302�!& 0 !2#0'8#2&#<6V)1.1'%, *',% 6'1 ,"2-',4#12'% 2#2&#

+-*#!3* 0+#!& ,'1+12&0-3%&5&'!&(.V (+ 713 4#02<1V.1'%, *',%Q5#

!3*230#"1S .30- ,"1S (.V (!#**13,"#01#03+ ,"%0-52&$ !2-0V

"#.0'4#"!-,"'2'-,1 ,"2&#,12'+3* 2#"2&#!#**15'2&&<6V)1Q5&'!& !2'4 2#12&#

3T ) WQ. ) 6 !3Q ,"!:U3 31'%, *',%. 2&5 71SYTB&'*#0- 312

!2'4 2'-,-$ 3T5 1- 1#04#"', -2&!#***',#1Q<!*- "',%-$. )5 1-,*7

- 1#04#"',&<6V)1V12'+3* 2#"1S .30-!#**1figure 2bR* ,#1U4#0131* ,#1Y

,"supplemental figure 2c, 2dTB# *1- 11#11#"2&##$$#!2-$ -,#V&-30

" 1 2',' .0#20# 2+#,2.0'-02-12'+3* 2'-,5'2&&<6V)1T % ',Q',!0# 1#". )V

<!*- "',%5 1-,*7- 1#04#"',1S .30-!#**1figure 2bR* ,#V4#0131* ,#Z

,"supplemental figure 2c, 2d ,"&<6V)1V+#"' 2#") WQ.3Q ," 3

!2'4 2'-,5 113 12 ,2' **7 22#,3 2#"',1S (.V (!#**10#* 2'4#2-1S .30-

!#**1T-**#!2'4#*7Q2#" 2 "#+-,120 2#2& 2(.V ()', 1# !2'4'27,#% 2'4#*7

0#%3* 2#1<6V)1.1'%, *',%Q ,"2&'10#%3* 2'-,.#01'121$-0+-0#2& ,-,#&-30

$-**-5',%(.V ()', 1#',&' '2'-,T

-"#2#0+',#'$<1V.1'%, *',%',(.V (V#6.0#11',%!#**1! , #$3**7

0#12-0#"5'2&',TVV&-301$-**-5',%)', 1#',&' '2'-,Q 1& 1 ##,- 1#04#"5'2&

4#+30 $#,' V20# 2#"(. 1GXRR+#* ,-+ !#**112'+3* 2#"5'2&;<1Q<1Q-0

$-03.2-#'%&2&-301.0'-02-&<6V)112'+3* 2'-,TB&'*# %0 "3 *',!0# 1#',2&#

&<6V)1V+#"' 2#" !2'4 2'-,-$) WQ.3Q ," 35 1- 1#04#"5'2&+-0#

.0-*-,%#"(.V (',&' '2'-,figure 2cR* ,#1[QSRQSSQSTQ2&#+ %,'23"#-$

. 2&5 70# !2'4 2'-,',1S (.V (!#**1 $2#0#'%&2&-301-$(.V ()', 1#

',&' '2'-,5 113 12 ,2' **7*#112& ,2& 2- 1#04#"',1S .30-!#**1figure 2cR

* ,#1UQVQWQXT ""'2'-, **7Q"#1.'2#+-"#0 2#&<6V)1V+#"' 2#"

0#.&-1.&-07* 2'-,-$.3',1S (.V (!#**1 $2#0#'%&2&-301-$(.V (

',&' '2'-,Q. ) !2'4 2'-,5 1+','+ *T(.V (',&' '2'-,5 1+ ',2 ',#"

2&0-3%&-322&'1.#0'-"Q 1#4'"#,!#" 7"#.&-1.&-07* 2'-,-$2&# !2'4 2'-,*--.

270-1',##U[Ufigure 2c; * ,#1[QSRQSSQSTT

B#,#62 11#11#"5�+-0#.0-*-,%#"(.V (',&' '2'-,'10#/3'0#"2-

#, *# ,# 0!-+.*#2#0#12-0 2'-,-$<6V)1.1'%, *',%T:,"##"Q20# 2+#,2-$

1S .30- ,"1S (.V (!#**15'2&" 1 2',' $-0TV&-301.0'-02-&<6V)1

12'+3* 2'-,0#13*2#"',+-0#!-+.*#2#. ) !2'4 2'-,',1S (.V (!#**1figure

2dT)'+'* 0*7Q !2'4 2'-,-$) WQ.3Q ," 35 10#12-0#"2-*#4#*1

!-+. 0 *#2-2&-1#- 1#04#"',1S .30-!#**1figure 2eT;-5#4#0Q 1

"#+-,120 2#"# 0*'#0Q"#1.'2#2&'1"#* 7#"0#12-0 2'-,-$%0-52&$ !2-01'%, *',%Q

&<6V)1$ '*#"2-$3**70#1!3#1S (.V (!#**1$0-+3:V+#"' 2#" .-.2-1'1

figure 2aT#0#13*21"#+-,120 2# ,'+.-02 ,2 '-*-%'!!-,1#/3#,!#-$<1V.

1'%, *',%0#5'0',% 7(.V (S 13 12 ,2' *.0-.-02'-,-$!#**1!-++'22-

.-.2-1'1"#1.'2#2&##4#,23 *0##12 *'1&+#,2-$.0-1304'4 *%0-52&$ !2-0

1'%, *',%T)'+'* 00#13*215#0#- 2 ',#"5&#,1S .30- ,"1S (.V (!#**1

5#0#20# 2#"5'2&'+ 2',' Q',"'! 2',%2##$$#!21 0#"3#2-',&' '2'-,-$(.V (

,",-2-2 0%#21-$2&#3:supplemental figure 3a-3d).

BCR-ABL Kinase Activity Attenuates Erythropoietin Receptor Signal

Transduction in CML Patient-derived CellsT-#62#,"-30$',"',%12- 6

. 2'#,2V"#0'4#"!#***',#Q5##4 *3 2#"5�(.V (0#5'0#1<1V.1'%, *',%',

3WXT!#**1Q5&'!.0#11 $3,!2'-, *#072&0-.-'#2',0#!#.2-0! V.SZT

.#* 2'4#2-;#072&0-*#3)#+' !#**1& 0 -0',%2&# !2'4 2',% 3T GXSY1 **#*#Q

3WXT!#**1#6&' '2,# 0*73,"#2#!2 *#*#4#*1-$ 3T#SRRY.&-1.&-07* 2'-,',2&#

1#,!#-$#072&0-.-'#2',&! supplemental figure 4aT)2'+3* 2'-,-$3WXT

!#**15'2&&! *#"2- +-"#12',!0# 1#', 3T !2'4 2'-,R-,#&-30.0#20# 2+#,2

5'2& (.V (3:.0'-02-&! 12'+3* 2'-,"'",-2 ..0#!' *7'+. !22&#

"#%0##-$ 3T !2'4 2'-,figure 3aT

B#,#62 11#11#"2&##$$#!2-$.0-*-,%#"(.V (',&' '2'-,TVTV&-301-,

&! V+#"' 2#" !2'4 2'-,-$ 3T ,""-5,120# +. 2&5 71',3WXT!#**1T 2'+#V

"#.#,"#,2',!0# 1#',&! V+#"' 2#") WQ.3 ," 3 !2'4 2'-,-!!300#"

5'2&#'2�" 1 2',' -0'+ 2',' .0#V20# 2+#,2figure 3b ,"supplemental

figure 4bT 12 2'12'! **71'%,'$'! ,2',!0# 1#',2&#"#%0##-$&! V+#"' 2#"

!2'4 2'-,-$ 3Tfigure 3c ,"supplemental figure 4c ," 13 12 ,2' *

',!0# 1#',. ) !2'4'27figure 3d5#0#- 1#04#"$-**-5',%TV&-301(.V (3:

.0#V20# 2+#,2T

JAK2 Activity Becomes Critical for EPO-R Signaling and K562 Cell

Survival After Prolonged BCR-ABL InhibitionT-"#2#0+',#'$0#12-0 2'-,-$

! V.1'%, *',%$-**-5',%.0-*-,%#"(.V (',&' '2'-,'1+#"' 2#"2&0-3%&2&#

! ,-,'! *! V. 3T 6'1Q5#32'*'8#"2#*#!2'4# 3T',&' '2-0

-+ ',#"TV&-30.0#V20# 2+#,2-$3WXT!#**15'2&

!-+.*#2#*7.0#4#,2#"&! V+#"' 2#" 3T !2'4 2'-, ,"0#V.&-1.&-07* 2'-,-$

) WQ.3Q ," 3figure 3e ,"figure 3f, lanes 8,9, 11 and 12T)'+'* 02-

2&#. 02' *0#1!3#$0-+ .-.2-1'1&<6V)1.0-4'"#13:V20# 2#"1S (.V (!#**1

figure 2aQ&! . 02' **70#1!3#13WXT!#**1$0-+'+ 2',' V+#"' 2#" .-.2-1'1

S[ ,"supplemental table 3]T&'1. 02' *0#1!3#$0-+'+ 2',' -0" 1 2',' V

+#"' 2#" .-.2-1'15 1!-+.*#2#*70#4#01#" 7!-V "+','120 2'-,-$

;-5#4#0Q',2#22',%-$ !2'4#(.V (Q

3WXT!#**1supplemental table 3T#- 1#04 2'-,113%%#122& 2 3T)', 1#'1

+','+ **7 !2'4#',2&#.0#1#,!#-$(.V ()', 1# !2'4'27Q 32! , #!-+#!0'2'! *

$-0%0-52&V$ !2-0V+#"' 2#"6!#**1304'4 *3.-,.0-*-,%#"(.V (',&' '2'-,T

BCR-ABL Inhibition Down-regulates Modulators of Negative Feedback

and Upregulates EPO-R. - #22#03,"#012 ,"2&#+#!& ,'1+10#1.-,1' *#$-0

2&#', '*'27-$<1V.12-#$$#!2'4#*720 ,1"3!#1'%, *',(.V (V#6.0#11',%!#**1Q

2'+#V"#.#,"#,2!& ,%#1',%*- *%#,##6.0#11'-,5#0# 11#11#"',3WXT!#**15#0#

20# 2#"5'2&" 1 2',' T:,2-2 *Q+'!0- 00 7 , *71'10#4# *#"S[RU%#,#12& 25#0#

1'%,'$'! ,2*7"'$$#0#,2' **7#6.0#11#" 2#'2�$-30Q#'%&2Q-0TV&-301-$" 1 2','

20# 2+#,2supplemental table 4T 1,#% 2'4#0#%3* 2-01-$. ) 6 !31'%, *',%

5#0#.0#4'-31*71&-5,2- #"-5,V0#%3* 2#"# 0*7 $2#06 !3',&' '2'-,',

(. 1GXRR!#**1XQ5#0# 1-,#"2& 2)#7,#% 2'4#0#%3* 2-01-$! V.1'%, *',%

',3WXT!#**15-3*" ##,0'!&#" +-,%%#,#11'%,'$'! ,2*7"-5,V0#%3* 2#" $2#0

$-30&-301-$" 1 2',' 20# 2+#,2T:,2-2 *QSXT%#,#1$-**-5#"2&'1. 22#0,

1>.0S$',!*3"',%5#**V!& 0 !2#0'8#"+#+ #01-$2&# 3 ) ,". ) 6 !3

,#% 2'4#$##" !)+ !&',#07SSOCS1QSOCS2QCISHQSPRY2QSPRY4QSPRED1QSPRED2Q

,"PIM1Q 32,-2 *7#6!*3"#"5#0#-2q!& 1DUSP4 ,"DUSP6figure 4aT

2�%#,#1 +-,%2#SXT.-2#,2*7"-5,V0#%3* 2#" $2#0$-30&-301-$

20# 2+#,25#0#"-5,120# +#$$#!2-01-$63 .31'%, *',%Q13!& 1!7!*',>S

CCND1 15#** 1%#,#12& 220 "'2'-, **7!-+.0'1#.3V+#"' 2#"20 ,1!0'.2'-, *

-32.32',!*3"',%20 ,1!0'.2'-,$ !2-01 11-!' 2#"5'2&20 ,1$-0+ 2'-,ETV5 ,"

MYC +-,%-2�.32 0%#21IER3 ,"EGR1T

B##6.*-0#"2&#SRVZ3,'/3#.0- #15&-1##6.0#11'-,',!0# 1#"$-**-5',%

" 1 2',' 20# 2+#,22-'"#,2'$7%#,#12& 2 #!-+#"#V0#.0#11#"$-**-5',%.0-*-,%#"

(.V (',&' '2'-,Q 1+'%&2 ##6.#!2#"-$.-1'2'4##$$#!2-01-$<1V.1'%, *',%Q

13!& 1 3T-02&#).$ +'*7)', 1#1T)#4#0 *,-,V! ,-,'! *"3 *V1.#!'$'!'27

.&-1.& 2 1#1>7)!1,-220 "'2'-, **7',4-*4#"',,#% 2'4#$##" !)0#%3* 2'-,-$

2&#. ). 2&5 75#0# +-,%2&'1%0-3.-$%#,#1'T#T>7)!SQ>7)!SUQ>7)!TSQ

>7)!TZT:,2#0#12',%*7Q! V.#6.0#11'-,',!0# 1#"1'%,'$'! ,2*7', 2'+#V

"#.#,"#,2+ ,,#0'," 1 2',' V20# 2#"!#**1T&#- 1#04#"!& ,%#1', 13 1#2-$

2#%#,#15#0#4 *'" 2#" 7/3 ,2'2 2'4#!./!.'," 1 2',' ,"'+ 2','

20# 2#"3WXT!#**1figure 4bT)'+'* 0!& ,%#1',%#,##6.0#11'-,5#0#- 1#04#"

',3WXT!#**120# 2#"5'2&23',&' '2-0!>RUTW[RSQ13%%#12',%2& 22&#

. ) 6 !3. 2&5 7'1.0'+ 0'*70#1.-,1' *#$-0#12 *'1&',%2&#,#% 2'4#$##" !)

,#25-0) ,"20 ,1!0'.2'-, *-32.32 11-!' 2#"5'2& 22#,3 2'-,-$+7#*-'"<1V.

1'%, *',%T

MEK/ERK-Dependent Negative Feedback Attenuates EPO-R Signaling in

K562 CellsT- 11#112&#$3,!2'-, *'+.-02 ,!#-$63V"#.#,"#,2,#% 2'4#

$##" !)2-5 0"<1V.1'%, *',% 22#,3 2'-,',6!#**1Q5#20# 2#"3WXT!#**15'2&

!>RUTW[RS$-0TV&-301T63',&' '2'-, *-,#',2&# 1#,!#-$&!

12'+3* 2'-,.0-"3!#"0- 312<!V*- "',%-$. )figure 4cR* ,#UQ5�# 1!-V

20# 2+#,25'2&" 1 2',' ,"!>RUTW[RS.0#4#,2#". )<!V*- "',%Q

"#+-,120 2',%2& 2. ) !2'4 2'-,3.-,63',&' '2'-,'1+#"' 2#" 7(.V (

,"'1,-22�#13*2-$#6-%#,-31-0 32-!0',#%0-52&$ !2-01figure 4cR* ,#U ,"

VQ 1& 1 ##,0#!#,2*7"-!3+#,2#"2--!!30', 6Q5�#;<11#!0#2'-, 7

*#3)#+'!!#**1! ,$-12#01304'4 *',2#22',%-$)', 1#',&' '2-020# 2+#,2TRT

&! 12'+3* 2'-,-$!>RUTW[RS.0#V20# 2#"!#**10#13*2#"',$302�. ) !2'4 2'-,Q

"#+-,120 2',%2& 2#$$'!'#,2! V.1'%, *',%',3WXT!#**1! , #0#12-0#" 763

',&' '2'-, *-,#figure 4cR* ,#U ,"* ,#Y ,"supplemental figure 5aT

-',4#12'% 2#53V"#.#,"#,2,#% 2'4#$##" !)" +.#,1! V.

1'%, *',% 22&#*#4#*-$ 3TQ5# 11#11#" 3T.&-1.&-07* 2'-,',0#1.-,1#2-

&! $2#0 TVV&-30.0#20# 2+#,25'2&!>RUTW[RST&! V+#"' 2#" 3T

!2'4 2'-,5 1!-+. 0 *#2-2& 2- 1#04#"5'2& TVV&-30" 1 2',' .0#20# 2+#,2

figure 4dRsupplemental figure 5bQ"#+-,120 2',%2& 263V"#.#,"#,2,#% 2'4#

$##" !) !21 22&#*#4#*-$! V. 3T',3WXT!#**1T--$302�',!0# 1#',&! V

+#"' 2#" 3T !2'4 2'-,5 1"#2#!2#"5&#,!#**15#0#.0#20# 2#"5'2&2&#

!-+ ', 2'-,-$" 1 2',' ,"63',&' '2-0$-0TV&-301.0'-02-&! 12'+3* 2'-,

figure 4dR* ,#1XQY4#0131* ,#ZT:,2&# 1#,!#-$&! 12'+3* 2'-,Q63

',&' '2'-,"'",-20#13*2', "#2#!2 *#',!0# 1#', 3T.&-1.&-07* 2'-,figure

4dR * ,#UT

-"#2#0+',#'$(.V ('1'21#*$13 (#!2#"2-63V"#.#,"#,2,#% 2'4#

$##" !)Q5##4 *3 2#"2&##$$#!2-$63',&' '2'-,3.-,2&#.&-1.&-07* 2'-,12 231

-$+3*2'.*#(.V (270-1',#0#1'"3#1Q',!*3"',%2&# !2'4 2'-,*--.270-1',##U[UT

!0-11 **(.V (.&-1.&-270-1',#0#1'"3#1',2#00-% 2#"Q*'22*#2-,-!& ,%#',

.&-1.&-07* 2'-,5 1- 1#04#"supplemental figure 5cQ13%%#12',%2& 21'+'* 02-

(. 1GXRR ,"',1& 0.!-,20 122-.31XQ(.V ( -2 *'1 ,"

#4 "#1 &'%&*#4#*-$63V"#.#,"#,2,#% 2'4#$##" !)0#%3* 2'-,T

K562 Cells Can Commit to Apoptosis Prior to Full Restoration of EPO-R

Signaling. &#*-,%"#* 7- 1#04#"',2�#12-0 2'-,-$! V+#"' 2#". 2&5 7

!2'4 2'-,',3WXT!#**11& 0.*7!-,20 1215'2&2� .'"TVV&-301 ,"$3**

0# !2'4 2'-,-$23 .3. 2&5 7',<1V12'+3* 2#"(. 1GXRR!#**1$-**-5',%

.0#V20# 2+#,25'2&4#+30 $#,' SRT&'1$',"',%Q!-3.*#"5'2&2&#', '*'27-$

&! 2-$3**70#1!3#3WXT!#**1$0-+" 1 2',' V+#"' 2#" .-.2-1'1Q13%%#1212& 2

3:V20# 2#"6!#**1$ !#!-+.#2',%$ 2#1S%0-52&$ !2-0V+#"' 2#"1304'4 *4#0131

!-++'2+#,22- .-.2-1'1.0'-02-!-+.*#2#0#12-0 2'-,-$<1V.1'%, *',%T-

$-0+ **72#122&'1Q5#','2' **7 11#11#"2&#)',#2'!1-$ .-.2-1'1',"3!2'-,',3:V

20# 2#"3WXT!#**1 75#12#0,'++3,- *-2TB&'*#13 12 ,2' *! 1. 1#VU!*# 4 %#

5 1"#2#!2#" $2#0TV&-301-$" 1 2',' 20# 2+#,2Q5#- 1#04#"4#07*'22*##4'"#,!#

-$ .-.2-1'1$-**-5',%ST&-301-$20# 2+#,2figure 5aT-"#2#!2! 1. 1#VU

!2'4'275'2& &'%�"#%0##-$1#,1'2'4'27Q5##+.*-7#" .* 1+-,'!, ,-1#,1-0

2#!&,'/3#! . *#-$"#2#!2',%1',%*#+-*#!3*#! 1. 1#VU!*# 4 %##4#,212&0-3%&

!& ,%#',*'%&21! 22#0',%',2#,1'27-$ %-*", ,-1&#**. '0figure 5bR 5cTST

&'1 11 70#*' *7"#2#!2#"! 1. 1#VU !2'4'27$-**-5',%-,*7#'%&2&-301-$

" 1 2',' 20# 2+#,2figure 5dQ"#+-,120 2',%2& 2 !-++'2+#,22- .-.2-1'1! ,

.0#!#"#$3**0#12-0 2'-,-$<1V.1'%, *',%',6. 2'#,2V"#0'4#"(.V (V ""'!2#"

!#**1T

BCR-ABL-Dependent Negative Feedback Differs from BRAFV600E and

Oncogenic Myeloid RTK-Mediated Negative Feedback in TF1 Cells. *2&-3%&

-2&2&#/3 *'27 ,"/3 ,2'27-$,#% 2'4#$##" !)$-**-5',%',&' '2'-,-$

(. 1GXRR ',+#* ,-+ ,"2&70-'"! ,!#0!#***',#1 ..# 02-"'$$#0$0-+

',&' '2'-,-$(.V (',6!#**1SRQSSQ5#1-3%&22-"'0#!2*7!-+. 0#2&#

+-*#!3* 0+#"' 2-01 ,""30 2'-,-$,#% 2'4#$##" !)',"3!#" 7(.V (Q

(. 1GXRR ," ,-,!-%#,'!.3',2 +#!#**3* 0!-,2#62TB#2�#$-0#

',20-"3!#"(. 1GXRRQ1UV:>Q1UV>ZUWG ,"(.V (',2-1S!#**1TB&'*#

&<6V)1V',"#.#,"#,21S.-.3* 2'-,1#6.0#11',%(.V (Q1UV:> ,"1UV

>ZUWG5#0#0# "'*7#12 *'1&#"Q+3*2'.*# 22#+.212-- 2 ', $ !2-0V',"#.#,"#,2

.--*-$(. 1GXRRV#6.0#11',%1S!#**1$ '*#"TB#! 0#$3**7123"'#"2&#'++#"' 2#

$ 2#-$1S!#**1',$#!2#"5'2&6: ,"

6:ZUWGT1-**-5',%20 ,1"3!2'-,Q',$#!2#"!#**15#0#1-02#" ,"2&#'0

%0-52&',&<6V)15 1+-,'2-0#"T1S 6:Q ,"

1S 6:ZUWG!#**1%0#51-+#5& 2+-0#1*-5*72& ,!-,20-*1S 6:<

!#**1Q13%%#12',%2& 2 -2&(.V (V ,"-,!-%#,'!1UV"#.#,"#,2,#% 2'4#

$##" !). 02' **7" +.#,&<6V)10#1.-,1'4#,#11figure 6aT:,2#0#12',%*7Q2&#

%0-52&0 2#-$1S (.V (5 11'%,'$'! ,2*71*-5#02& ,2& 2-$1S 1UV:>

,"1S 1UV>ZUWGQ13%%#12',%2& 2,#% 2'4#$##" !)#*'!'2#" 7(.V (

"'$$#01',+ %,'23"#$0-+2& 2#*'!'2#" 7-,!-%#,'!1UT:,!-,20 12Q2&#%0-52&-$

1S (. 1GXRR5 11'%,'$'! ,2*7 22#,3 2#"0#* 2'4#2- **-2�!#***',#1"#1.'2#

2&#.0#1#,!#-$&<6V)1Q13%%#12',%2& 2#6.0#11'-,-$(. 1GXRR.0-$-3,"*7

"'+','1&<6V)10#1.-,1'4#,#11T:,"##"Q&'%&*#4#*1-$.3S T !2'4 2'-,5#0#

- 1#04#"',1S 6:

#4#,23 **7- 1#04#"&<6V)1V13..-02#"%0-52&-$2#!#**1Q.3S T !2'4 2'-,

5 113 12 ,2' **7"'+','1&#"5&#,2&'1-!!300#"supplemental figure 6)T&'1

- 1#04 2'-,13%%#1212& 2!-+.#,1 2'-,$-0(. 1GXRR1'%, *',%2&0-3%&

22#,3 2'-,-$(. 1GXRRV"'0#!2#",#% 2'4#$##" !)+ 7 #,#!#11 07$-0%0-52&

$ !2-0V+#"' 2#".0-*'$#0 2'-,-$1S (. 1GXRR!#**1T

-2#12'$2&#+-*#!3* 0+#"' 2-01-$,#% 2'4#$##" !)#*'!'2#" 7 ,

-,!-%#,'!.3"'$$#0$0-+(.V (Q5#$'012 11#11#"2 2#-$-,!-%#,#

""'!2'-,+#"' 2#" 71UV:>#6.0#11'-,',1S!#**1T)'+'* 02-1S (.V (

!#**120# 2#"5'2&(.V (3:Q%0-52&$ !2-0V"#.0'4#"1S 1UV:>!#**1 0#

1'%,'$'! ,2*7+-0#1#,1'2'4#2-20# 2+#,25'2&2&#.-2#,21#*#!2'4#1U',&' '2-0

TTR/3'8 02',' 5&#,!-+. 0#"5'2&%0-52&$ !2-0V"#.0'4#"1S .30-!#**1

figure 6bT;-5#4#0Q',!-,20 122-5& 25#.0#4'-31*7- 1#04#"5'2&1S (.V

(!#**1Q&<6V)1+-0#$3**70#1!3#"1S 1UV:>!#**1$0-+ TTRV+#"' 2#"

.-.2-1'1T- 11#115&#"30 2'-,-$,#% 2'4#$##" !)',1S 1UV:>

!#**1$-**-5',%)', 1#',&' '2'-,"'$$#01$0-+5& 25#- 1#04#"',1S (.V (

!#**1Q5#20# 2#"1S 1UV:>!#**15'2& TTR$-04 07',%*#,%2&1-$2'+#.0'-02-

&<6V)112'+3* 2'-,T:,!-,20 122-1S (.V (!#**1Q&<6V)1V+#"' 2#"

!2'4 2'-,-$) W ( ,".3S T5 1$3**70#12-0#"$-**-5',%-,*725-&-301-$

)', 1#',&' '2'-,figure 6cQ13%%#12',%2& 2Q1'+'* 02-5& 2'1- 1#04#"$-**-5',%

(. 1GXRR',&' '2-020# 2+#,2',+#* ,-+ ,"2&70-'"! ,!#0!#***',#1Q1UV

:>V"#.#,"#,2,#% 2'4#$##" !)0 .'"*7"'+','1$-**-5',%1UV',&' '2'-,T

:,2#0#12',%*7Q2&#)',#2'!1-$<6V)1.V+#"' 2#" 3.&-1.&-07* 2'-,$-**-5',%

)', 1#',&' '2-020# 2+#,2"'$$#01 #25##,1S (.V ( ,"1S 1UV:>!#**1T

:,1S (.V (!#**1Q. 02' * 30#.&-1.&-07* 2'-,5 1- 1#04#" $2#0TVV&-301

-$" 1 2',' 20# 2+#,2figure 2c5&'*#.0-*-,%#"1UV:>',&' '2'-,5 1

,#!#11 07$-0<6V)1.V+#"' 2#" 3.&-1.&-07* 2'-,',1S 1UV:>!#**1T

#0#13*21&'%&*'%&22 12 ,2' *"'$$#0#,!#1',,#% 2'4#$##" !)#*'!'2#" 7

(.V ( ," ,-,!-%#,'!.3T

DISCUSSION

&##$$'! !7-$(.V (3:2� .7$-06130. 11#12& 2-$ **-2> V

..0-4#"2 0%#2#")', 1#',&' '2-01 ,"2�# 7.0-4'"#12&#+-12!-+.#**',%

!*','! *#6 +.*#-$-,!-%#,# ""'!2'-,T 30.--03,"#012 ,"',%-$2&#+-*#!3* 0

1'1-$2&'1.&#,-+#,-,& 1 ##,"3#Q',. 02Q2- * !)-$#$$#!2'4#+-"#*1T;#0#Q

5#20 ,1'#,2*7#6.-1#"6!#**12-" 1 2',' ,"'"#,2'$'#""30 *#!& ,%#1',

#$$#!2-01-$<1V.1'%, *',%Q5&'!&*')#*7#6.* ',2&#!72-2-6'!#$$#!21-$(.V (

',&' '2'-,TB#2&#,#12 *'1&#" ,"4 *'" 2#" ,'1-%#,'!1712#+-$(.V (V

+#"' 2#"-,!-%#,# ""'!2'-, ,"',4#12'% 2#"'21+-*#!3* 0$# 230#1TB#$-3,"

2& 2(.V (V+#"' 2#"-,!-%#,# ""'!2'-,'12�#13*2-$.&71'-*-%'!,#% 2'4#

$##" !)',&' '2'-,2& 2$3,!2'-, **7 ,".#01'12#,2*7" +.#,1<1V.1'%, *',% 2

+3*2'.*#,-"#1Q',!*3"',%Q',2&#! 1#-$! V.Q 22&#*#4#*-$<1V.20 ,1!0'.2'-,T 1

5'2&(. 1GXRR',+#* ,-+ !#**1Q(.V (#12 *'1 &'%&*#4#*-$63V

"#.#,"#,2,#% 2'4#$##" !)T.#*'#$$0-+63V"#.#,"#,2,#% 2'4#$##" !)'1

0#/3'0#"2-#, *#$3**0#12-0 2'-,-$<1V.1'%, *',% ,"-,*7-!!301 $2#0.0-*-,%#"

(.V ()', 1#',&' '2'-,T:+.-02 ,2*7Q,#% 2'4#$##" !)" +.#,1<1V.1'%, *',%

13 12 ,2' **7*-,%#0',6!#**12& ,5& 2& 1 ##,0#.-02#"',(. 1GXRRV

#6.0#11',%+#* ,-+ !#**1T 1 !-,1#/3#,!#Q<1V.1'%, *',%'1',13$$'!'#,22-$3**7

0#1!3#6!#**1$0-+2&#!-+.#2',%$ 2#-$ .-.2-1'1Q5&'!&$-02&#$'0122'+#Q5#

"#+-,120 2#2- #','2' 2#" 1# 0*7 1#'%&2&-301$-**-5',%3:20# 2+#,2T 1

0#13*2-$2&'1',2#0.* 7 #25##, !-++'2+#,22- .-.2-1'1 ,"2&#"#! 7-$

,#% 2'4#$##" !)2& 2$ !'*'2 2#10#12-0 2'-,-$.0-1304'4 *%0-52&$ !2-01'%, *',%Q

6!#**1"#+-,120 2# .0-$-3,"0#*' ,!#3.-,(.V ()', 1# !2'4'27$-0

1304'4 *figure 7aR7bT

(-2.#0'+#,2 * ,"!*','! *#4'"#,!#13%%#122& 22&##$$#!2'4#,#11-$

(. 1GXRR',&' '2'-,',+#* ,-+ !-,20 1211& 0.*75'2&(.V (',&' '2'-,',

6TIn vitroQ(. 1GXRR+#* ,-+ !#***',#1* 0%#*7$ '*2-3,"#0%- .-.2-1'1

5&#,20# 2#"5'2&(. 1',&' '2-0113!& 14#+30 $#,' TTVTW ," *2&-3%&2&#

+ (-0'27-$+#* ,-+ . 2'#,2120# 2#"5'2&4#+30 $',' 0#1.-,"2-1-+#"#%0##Q

+-12$ '*2- !&'#4#"##.0#+'11'-,1VT ,3+ #0-$(. 1GXRRV#6.0#11',%

+#* ,-+ Q!-*-0#!2 *Q ,"2&70-'"! ,!#0!#***',#1! , #0#1!3#"$0-+(. 1

',&' '2-020# 2+#,2 7.3*'% ,"1in vitroQ*# "',%2-13 1#/3#,20# !2'4 2'-,-$

6 !3 ," 31'%, *',% 11--, 1-,#&-30 $2#0(. 1',&' '2-020# 2+#,2YVSST

:,!-,20 12Q2&#!-00#1.-,"',%2'+#$0 +#5#- 1#04#"',(.V (V#6.0#11',%!#**1

'1+ 0)#"*7"'$$#0#,2S-,*7. 02' *0#12-0 2'-,-$<1V.1'%, *',%-!!301 $2#0#'%&2

&-301-$3:20# 2+#,2Q 25&'!&2'+# !-+.#2',%!-++'2+#,22- .-.2-1'1& 1

*0# "7 ##,','2' 2#"', 13 12 ,2' *.0-.-02'-,-$!#**1T

>#1.'2#2&#!*','! *"'$$#0#,!#1- 1#04#"5'2&',&' '2-01-$(. 1GXRR ,"

(.V (Q2#25--,!-.0-2#',11& 0#1-+# '-*-%'! *.0-.#02'#1T(-2& 0#

. 2&-*-%'! **7 !2'4 2#"!72-1-*'!)', 1#12& 2#12 *'1& ,"#4 "# &'%&V"#%0##-$

63V"#.#,"#,2,#% 2'4#$##" !)XT *1-Q 13 12 ,2' *!-0#!-+.-,#,2-$2&#

.320 ,1!0'.2'-, *-32.32'11'+'* 0*7"'+','1&#"5&#,2#-,!-.0-2#',1 0#

',&' '2#"Q',!*3"',%.3. 2&5 7#$$#!2-01Q,#% 2'4#$##" !)0#%3* 2-01Q ,"

"-5,120# +20 ,1!0'.2'-,$ !2-01T1-0',12 ,!#Q -2&)', 1#1 ..# 02-',"3!#2&#

#6.0#11'-,-$+#+ #01-$2&#).0-327%#,#$ +'*7Q5&'!&27.'! **72 0%#22&#.3

. 2&5 7$-0,#% 2'4#$##" !)',&' '2'-, 22&#*#4#*-$. 1Q. ) ,"3.120# +

.31T

�# 0#Q&-5#4#0Q,-2 *#"'$$#0#,!#1',2&#,#% 2'4#$##" !),#25-0)1

%#,#0 2#" 7(.V ( ,"(. 1GXRRQ. 02'!3* 0*75'2&0#1.#!22-5�#

$##" !)'1-.#0 *#T 22&#<1V.*#4#*Q(.V ()', 1# !2'4'27"-5,V0#%3* 2#1

! V.#6.0#11'-,',3WXT!#**1Q* 0%#*72&0-3%&63 .31'%, *',%Q5&'!&+ 7

$302�!-,20' 32#2-2&#"#* 7',0#12-0',%.0-V1304'4 *<1V.V+#"' 2#"1'%, *',%

$-**-5',%(.V (',&' '2'-,T:,!-,20 12Q#6.#0'+#,2 *#4'"#,!#13%%#1212& 2

2�#'113$$'!'#,2.3#6.0#11'-,',(. 1GXRR+#* ,-+ ,"!-*-0#!2 *! ,!#0

!#**12-0 .'"*70#12-0#.0-V1304'4 *1'%, *',%YVSRT ""'2'-, *"'$$#0#,!#1#6'12',

"-5,120# +!-+.-,#,21-$,#% 2'4#$##" !)Q. 02'!3* 0*7 22&#*#4#*-$.3

.&-1.& 2 1#1Q5&'!&2 0%#2#'2�,3!*# 0-0!72-1-*'!.3$-00#%3* 2'-,

"-5,120# +-$2&#-,!-%#,'!',13*2T:,1& 0.!-,20 122-2&##$$#!2-$(. 1GXRR

',&' '2'-,',+#* ,-+ !#**15�#"-5,0#%3* 2'-,-$2&#"3 *1.#!'$'!'27

.&-1.& 2 1#>7)!X'1 .. 0#,2 2+3*2'.*#*#4#*1XQSRQ5#$ '*#"2-"#2#!2>7)!X

22&#.0-2#',*#4#*',6!#**1" 2 ,-21&-5, ,"Q', %0##+#,25'2&2&'1

- 1#04 2'-,Q(.V (',&' '2'-,$ '*#"2-"-5,V0#%3* 2#DUSP6 #6.0#11'-,T#

"'$$#0#,!#113%%#122& 263V"#.#,"#,2,#% 2'4#$##" !)'1-,!-%#,#V1.#!'$'!T

6-0#-4#0Q',(.V (V#6.0#11',%6!#**1Q$##" !)#$$#!2-01-$2&#. 0 **#*

3 ) . 2&5 7 0# !2'4 2#"#T%TSOCS1 ," SOCS2Q5&'*#',(. 1GXRR

+#* ,-+ !#**12#$##" !)#$$#!2-01 0# 1#,2T#0#13*210# $$'0+2& 22&#

,#25-0)1+#"' 2',%,#% 2'4#$##" !)',&' '2'-,-$-,!-%#,'!1'%, *',% 0#

+3*2'$ !#2#"Q.*#'-20-.'!Q ,"!-,2#62V"#.#,"#,2T:,"##"Q#6.0#11'-,-$-,!-%#,'!

**#*#1-$1U',1S!#**1"#+-,120 2#12& 2 !2'4 2'-,-$ !*','! **70#*#4 ,2

+7#*-'".3#*'!'21 ,#% 2'4#$##" !)0#1.-,1#2& 2'1!*# 0*7"'12',!2$0-+2& 2

#*'!'2#" 7(.V (',2 +#!#**3* 0!-,2#62T1302{"7'10#/3'0#"2-

"'11#!22&#'+.-02 ,!#-$2&#- 1#04#"/3 *'2 2'4# ,"/3 ,2'2 2'4#"'$$#0#,!#1',

,#% 2'4#$##" !)#*'!'2#" 72#)', 1#1T

305-0).0-4'"#1',1'%&2',2-2�-*#-$ 3T',2&#+-*#!3* 0

. 2&-%#,#1'1-$6Q5&'!&& 1 ##, 13 (#!2-$!-,1'"#0 *#!-,20-4#017T:2'1

),-5,2& 2612#+!#**1.#01'12$-0 2*# 121#4#0 *7# 01',+-12Q'$,-2 **Q6

. 2'#,21T:2& 1 ##,1.#!3* 2#"2& 213!!#11$3*',&' '2'-,-$(.V ()', 1#

!2'4'27',612#+!#**1+ 7 #',13$$'!'#,22-#*'!'2 .-.2-1'1',2#!#**1"3#2-

2&#'00#1'"#,!#', !72-)',#V0'!& -,#+ 00-5+'!0-#,4'0-,+#,22& 2+ ',2 ',1

2&#'04' '*'27"#1.'2#(.V (3:20# 2+#,2TXT ,#%0-3..0-4'"#"#4'"#,!#

2& 2!-+ ',#"(.V ( ," 3T',&' '2'-, !&'#4#1+-0#!-+.*#2##0 "'! 2'-,-$

6!#**1',!-,"'2'-,#"+#"' in vitroTYQ5&'*# ,-2�%0-3.0#!#,2*7

"#+-,120 2#"2& 2 3T'1!-+.*#2#*7"'1.#,1 *#$-0,# 0*7 ** 1.#!21-$(.V

(V+#"' 2#"+7#*-'""'1# 1#','2' 2'-, ,"+ ',2#, ,!#TZT *2&-3%&2#

123"'#1-$$#0!-,$*'!2',%4'#51-,2&#'+.-02 ,!#-$ 3T !2'4'27$-06

. 2&-%#,#1'1Q-300#13*21 ,".0-.-1#"+-"#*-$(.V (V"#.#,"#,2 22#,3 2'-,

-$<1V.1'%, *',%0#1-*4#12&'1 .. 0#,2. 0 "-6TB&#,(.V ('1 !2'4#Q 3T

.* 71*'22*#-0,-0-*#',1'%, *20 ,1"3!2'-,"3#2-63V"#.#,"#,2,#% 2'4#

$##" !)V+#"' 2#" 22#,3 2'-,-$<1V.1'%, *',%T $2#0.0-*-,%#"(.V (

',&' '2'-,Q,#% 2'4#$##" !)'10#*'#4#" ," 3T+ 7 #!-+#!0'2'! **7'+.-02 ,2

1 +#"' 2-0-$) W.&-1.&-07* 2'-,',2#22',%-$#62#0, *%0-52&$ !2-01T

30" 2 .0-4'"#+#!& ,'12'!13..-02$-0!*','! *#$$-0212-!-+ ',#(.V (3:1

5'2&.-2#,2 3T3:1Q5&'!& 0#.0#"'!2#"2-& 4#,- !2'4'27',2&# 1#,!#-$

(.V (',&' '2'-,Q 32+'%&2"#+-,120 2# 17,2'!*#2& *',2#0 !2'-,5'2&(.V

(3:1',2#22',%-$#6-%#,-31%0-52&$ !2-01Q1.#!'$'! **7 1 !-,1#/3#,!#-$

2&#"#! 7',,#% 2'4#$##" !)5#"#1!0' #�#T:$ 3T1#04#1 0#"3," ,2

$3,!2'-,',$ !'*'2 2',%.0-1304'4 *<1V.+#"' 2#"1'%, *',%',2&# -,#+ 00-5

+'!0-#,4'0-,+#,2Q *2#0, 2'4# ..0- !'** #0#/3'0#"T

&#-,!-%#,'!1&-!)+-"#*-$-,!-%#,# ""'!2'-,U5 1.0-.-1#"5'2&

*'+'2#"13..-02',%" 2 Q ,"2&#+-*#!3* 0+#"' 2-01-$-,!-%#,# ""'!2'-,& 4#

0#+ ',#"#*31'4#T 30" 2 120-,%*7'+.*'! 2#.#01'12#,2,#% 2'4#$##" !)',2&#

.0-+-2'-,-$ .-.2-1'1$-**-5',%)', 1#', !2'4 2'-,Q ,"2&31.0-4'"#4 *3 *#

+-*#!3* 0+#!& ,'12'!',1'%&21',2-2&# 1'1-$ -2&-,!-%#,# ""'!2'-, ,"2&#

-,!-%#,'!1&-!)+-"#*T�#!#,2 ..0#!' 2'-,-$&-50 .'"*7,#% 2'4#$##" !)

"#! 71',(. 1GXRRV#6.0#11',%1712#+1 ,"2�# 7$ !'*'2 2#1.0-1304'4 *1'%, *

20 ,1"3!2'-, 7<1V.1& 1*#"2-20# 2+#,2 ..0- !& 2!-+ ',#4#+30 $#,'

5'2&+3*2')', 1#<1V.',&' '2-01T;-5#4#0Q%'4#,2&#%0-5',%,3+ #0-$1'%, *',%

+-*#!3*#12& 2& 4# ##,$-3,"2- #!-+# !2'4 2#"$-**-5',%',&' '2'-,-$

(. 1GXRRQ1 $# ,"#$$#!2'4#',&' '2'-,-$ **0#*#4 ,2<1V.1+ 7.0-4#"'$$'!3*2T

30123"'#1-$(.V (V+#"' 2#"-,!-%#,# ""'!2'-,13%%#12 , *2#0, 2'4#

..0- !& '+#" 2.-2#,2' 2',%,#% 2'4#$##" !)',2#22',%-$',&' '2'-,-$

. 2&-*-%'! **7V !2'4 2#")', 1#1Q5&'!&'1.0#"'!2#"2-#,& ,!#-,!-%#,# ""'!2'-,

,"',!0# 1#1#,1'2'4'272-2 0%#2#"2� .7T:, ""'2'-,2-.-11' *7$ !'*'2 2',%

"##.#0!*','! *0#1.-,1#1Q2&'1120 2#%7+ 7 # ..*'! *#2- 0- "0 ,%#-$

+ *'%, ,!'#1 11-!' 2#"5'2& !2'4 2',%+32 2'-,1', !2'-, *#1'%, *',%+-*#!3*#1T

$$-0212-$302�"'11#!2 ,"+-"3* 2#+-*#!3* 0+#!& ,'1+1-$,#% 2'4#$##" !)

',0#*#4 ,22'113#!-,2#621 0#0#/3'0#"2-$-0+ **72#122&'1.0#"'!2'-,T

EXPERIMENTAL PROCEDURES

Cell Line Propagation and Isogenic Cell Line Generation

#***',#15#0#.0-. % 2#"',.!6:SXVR+#"'3+13..*#+#,2#"5'2&SR$$#2 *

-4',#1#03+1()R +#% )!'#,2'$'!QV%*32 +',#Q ,".#,'!'**', 120#.2-+7!',

:,4'20-%#,T3WXT ,"37ZST!#**15#0#.30!& 1#"$0-+ +#0'! ,7.#3*230#

-**#!2'-, T1S!#**15#0# )',"%'$2$0-+6'!& #*-+ 11-,B 1&',%2-,

7,'4#01'27Q)2T-3'1Q6 T **!#***',#15#0# 32&#,2'! 2#" 7!0-+#% ). , *71'1T

-%#,#0 2#'1-%#,'!!#***',#1Q1S!#**15#0##,%',##0#"2-#6.0#112&##!-20-.'!V

0#!#.2-0!-V.2&0-3%&0#20-4'0 *20 ,1"3!2'-,.6 B)V!-..* 1+'" 1

.0#4'-31*7"#1!0' #"T[T1SV!-V.!#**13,"#05#,2 1#!-,"0-3,"-$0#20-4'0 *

20 ,1"3!2'-,5'2&.6)GV.30-Q.6)GV(.V ( ,".30-+7!',1#*#!2'-,T

1S (.V (!#**15#0#1#*#!2#"$-0%0-52&V$ !2-0',"#.#,"#,!#5&'*#1S .30-

!#**15#0#13..*#+#,2#"5'2&T,% +&<6V)1!#.0-2#!&3,"#0,-0+ *%0-52&

!-,"'2'-,1T

Kinase Inhibitors and Drug Treatments

:+ 2',' ,"" 1 2',' 5#0#.30'$'#" 27)1TRUTW[RSQ ," TTR

5#0#.30!& 1#"$0-+)#**#!)!&#+T **"03%#6.-130#15#0#.#0$-0+#" 2 "#,1'27

-$W×SRX!#**1 +T1-0!72-)',#12'+3* 2'-,Q!#**15#0#12 04#"',RTS$1()V.!6:

1',"'! 2#" ,"13 1#/3#,2*712'+3* 2#"5'2&S7 +&3+ ,#072&0-.-'#2',

&! .>)712#+1-0SR,% +-$&<6V)1T> 1 2',' ;>! ,">"03%

#6.-130#15#0#.#0$-0+#" 1"#1!0' #".0#4'-31*7STT

Statistical Analyses

**12 2'12'! * , *71#15#0#.#0$-0+#"',!0'1+<0 .&! "31',% 25-V5 7

- G 5'2&(-,$#00-,'.-12V2#121T

Quantitative Phosphoproteomics and DAVID Functional Analysis

3WXT!#**15#0#%0-5,$-01'6" 71',!312-+'8#".!6:SXVR13..*#+#,2#"5'2&

&# 47 + 0'"%#:1-2-.# -0 2-0'#1R6VTTXW ,"6VTTVY-0*'%&2)'%+ V

*"0'!&UR+% 0%',',#QVR+% 71',#Q ,"SR$"' *78#"1():,4'20-%#,.0'-0

2-"03%20# 2+#,2T&#!#SRR!&-1.&-1! ,3'2#**)'%, *',%#!&,-*-%75 1

31#"2-#,0'!&.&-1.&-270-1',#!-,2 ',',%207.2'!.#.2'"#1T-0#"3!#1 +.*#

!-+.*#6'27.0'-02-6) 6) , *71'1Q.&-1.&-270-1',#.#.2'"#15#0#$0 !2'-, 2#"

12#.V5'1#3,"#0 *) *',#!-,"'2'-,1TR+6 ++-,'3+$-0+' 2#Q.;SRTU5'2&

',!0# 1',% +-3,21-$ !#2-,'20'*#W$ -QSR$ -QSW$ -QTR$ -Q[R$

-T!#.2'"#15#0#1#. 0 2#" ," , *78#"31',% , ,-V!-*3+,!-3.*#"2-

A 0 '0 .P�+-)!'#,2'$'! 22)16 11).#!20-+#207-0#1 !'*'27T

,',V&-31#1-$25 0# , *71'1.0-%0 +5 131#"2-#620 !2/3 ,2'2 2'4#',$-0+ 2'-,

$-0 **'"#,2'$'#".#.2'"#1$0-+# !&, ,-V , *71'1$-0 **2'+#.-',21T;# 2+ .

0#.0#1#,2 2'-,-$2&#.&-1.&-.0-2#-+'!" 2 5 1%#,#0 2#"31',%<-V

&22.S 555T 0- "',12'232#T-0% ! ,!#0 1-$25 0# <-V TB#$3,!2'-, **7

!& 0 !2#0'8#".&-1.&-1'2#1"30 *7 *2#0#" 7;>!" 1 2',' 20# 2+#,20#* 2'4#2-

**'"#,2'$'#".&-1.&-.0-2#',1 !)%0-3,"31',%2&#> G:>2--*5'2&"#$ 3*2

. 0 +#2#01URQUS

Cell Lysis and Protein Immunoprecipitation

#**15#0#*71#"', 3T:! 3$$#0WR+60'1.;YTXQSRR+6- *QS+6> Q

S+6< QRTW$-!VRQRTS$0'2-,-0. ):! 3$$#0WR+60'1.;YTWQSTW+6

- *QXTW+66%*TQW$%*7!#0-*QRTT$-!VR13..*#+#,2#"5'2&S$.0-2# 1# ,"

S$.&-1.& 2 1#',&' '2-01 * '-!&#+T1-0 3T'++3,-.0#!'.'2 2'-,1Q

,-0+ *'8#"*71 2#15#0#23+ *#"-4#0,'%&2 2V°5'2& ,2'V2-2 * 3T ,2' -"7

SSSRR#**)'%, *',%#!&,-*-%7Q! 2T3UTURT:++3,-.0#!'.'2 2#" 3T5 1

!-**#!2#"5'2&.0-2#', >7, # "1:,4'20-%#,T1-0. )<!V.3**"-5, 11 71Q

,-0+ *'8#"*71 2#15#0#23+ *#"$-0S&0 2V°5'2&TRμ-$. ) 11 7.# %#,2

6'**'.-0#R3SVVTYZT

Antibodies, Western Immunoblot, and Phospho-Flow Cytometry

#***71 2#15#0#0#1-*4#" 7)>)V! < ,"20 ,1$#00#"2-,'20-!#**3*-1# 1

"#1!0' #".0#4'-31*7STT!&-1.&-V ,"2-2 * ,2' -"'#1$-0) W (.&-1.&-V

#X[V #X[[! 2T[UWS ,"[UXUQ.3S T.&-1.&-VTRT #TRV! 2TVUYR ,"

[SRYQ 3.&-1.&-V)VYU! 2TVRXR ,"[TYTQ)X.&-1.&-V)TUW )TUX! 2T

TTSS ,"TUSYQ.3.&-1.&-V#TRY! 2TUSZSQ 3T.&-1.&-V#SRRY! 2T

UYYX ,"UTURQ(..&-1.&-V#SYY! 2TU[RSQ! (.&-1.&-V#TVW ,"

.&-1.&-V#TRV! 2TTZXS ,"URR[Q ,"!*# 4#" )!U! 2T[XXV5#0#

.30!& 1#"$0-+#**)'%, *',%#!&,-*-%7T! (! 2T !TR ,"2-2 *. )! 2TRWV

WSX ,2' -"'#15#0#.30!& 1#"$0-+6'**'.-0#T! (.&-1.&-V#SUV! 2T

!URSS ,"! (.&-1.&-V#TWS! 2T !URSV ,2' -"'#15#0#.30!& 1#"

$0-+ %#,2T-2 *< !>;! 2T1!VTWYYZ5 1.30!& 1#"$0-+) ,2 038T

"711#7',$0 0#"'+ %',%2#!&,-*-%7 ,"1-$25 0#:V .('-1!'#,!#15 131#"

$-05#12#0,'++3,- *-24'13 *'8 2'-, ,"/3 ,2'2 2'-,5 1+# 130#" 7.'6#*

',2#%0 2#"',2#,1'27T*# 4#"! 1. 1#VU5 1+# 130#" 7$*-5!72-+#20731',%

1:V!-,(3% 2#" ,2'V !2'4#! 1. 1#VU ,2' -"7(>R! 2T3WWRVZRT , *71'1-$

.3.&-1.&-07* 2'-, 7$*-5!72-+#2075 1.#0$-0+#" 1.0#4'-31*70#.-02#"

STT

Gene Expression Analysis and Quantitative PCR

-2 *!#**3* 0.- 5 1#620 !2#"32'*'8',%2&#A' %#,.-# 17)'2T1-0:**3+', %#,#

#6.0#11'-, , *71'1Q.- ',2#%0'275 1 11#11#"-, ('- , *78#031',%2&# %'*#,2

.- XRRR- ,-3'2WRXYVSWSSQ ,"!.- 5 1%#,#0 2#" 7 + '-,:**3+',

-2 *!0#..- +.*'$'! 2'-,)'2 6:SY[ST)3.#0)!0'.2:::,4'20-%#,5 131#"

2-%#,#0 2#!>- $0-+Tμ%-$#620 !2#"2-2 *!#**3* 0.- T) +.*#15#0#&7 0'"'8#"

2-2&#:**3+', ;VST.* 2$-0+ 72)1<#,-+'!1-0# ," -2&0 5!-,20-*

,"1 +.*#.0- #',2#,1'2'#15#0#!-,4#02#"2-#6.0#11'-,#12'+ 2#1 $2#0 "(312',%

$-0 00 7 !)%0-3,"Q4 0' ,!#12 '*'8 2'-,Q ,",-0+ *'8 2'-,Q **5'2&2&#*3+'

.'.#*',#!6:>SSZVXYUVZT>'$$#0#,2' *%#,##6.0#11'-,5 1 11#11#" 1 2'+#

!-301#5'2& 25-V12#.0#%0#11'-,120 2#%7!-+ ',',%*# 12V1/3 0#1 ,"12#.5'1#

0#%0#11'-,2-'"#,2'$7%#,#15'2&1'%,'$'! ,22#+.-0 *#6.0#11'-,!& ,%#1 #25##,

#6.#0'+#,2 *%0-3.1!6:>SSXVZSUUUT<#,#15#0#!-,1'"#0#"1'%,'$'! ,2*7

"'$$#0#,2' **7#6.0#11#"'$2 0-1# 2 $ *1#"'1!-4#070 2#*#112& ,S$/V4 *3#

0RTRST-,$'0+ 2-07/!. , *71'15 1.#0$-0+#"31',% /6 ,.0- #1 ,"

/6 ,7,'4#01 *6 12#06'6:::,4'20-%#,S< !>;;1RTYWZ[[S%SQ) )S

;1RRYRWSXV1SQ<.(SR;1RSRXWV[Z+SQ)!.#V;1RS[UWVST1SQ! .

;1RR[W[VTY+ST6.0#11'-, 00 7" 2 %#,#0 2#"',2&'1123"75#0#"#.-1'2#"',

2&#- 2'-, *:,12'232#1-$;# *2&-:;-(:<#,#6.0#11'-, +,' 31< Q

!!#11'-,,3+ #0S<)WSRZU

&22.S 555T,! 'T,*+T,'&T%-4 %#- /3#07 !!T!%'[ !!-<)WSRZUT

Single Molecule Imaging of Caspase-3 Activation Using Dimeric Au Nanoshells

#!&,'/3#15#0# " .2#"$0-+TS ,"+-"'$'#"',3,.3 *'1&#"+#2&-"1T

(-,Q#T3,Q ,"T)T0 ')T(0'#$*7Q . '0-$+ %,#2-.* 1+-,'!

U,RTV1#TTX V)' T%-*" 3, ,-1&#**1WR,+*',)#" 7 .#%7* 2#"V.#.2'"#

# 0',% 1#*#!2'4#! 1. 1#VU!*# 4 %#1'2#5#0#17,2'8#"T71 2#15#0#

.0#. 0#"$0-+3WXT!#**1.0#20# 2#"$-0#'%&2&-3015'2&>6) -0" 1 2',' Q ,"

',20-"3!#"2-, ,-1#,1-01'++- '*'8#"-, %* 11$*-5!& + #0T 1 !-,20-*SRR

368>G>V!+)5 1 ""#"$-02&0##&-301T:+ %',%5 1.#0$-0+#"-, ,',4#02#"

+'!0-1!-.#-')-,'V-32$'22#"5'2& " 0)$'#*""07!-,"#,1#0 ,"0#!-0"#" 2

2#+.-0 *0#1-*32'-,-$SR;831',% ,6>"#2#!2-0 ,"-0'P-,RWST6WST.'6#*

!&'.T:,2#,1'2720 (#!2-0'#1-$# !&, ,-. 02'!*#. '0,-YW5#0# , *78#" 7

:+ %#T-2 *!*# 4 %##4#,21- 1#04#"[R+',32#1$-**-5',%*71 2#',20-"3!2'-,

5#0#!-3,2#"Q,-0+ *'8#" % ',12!-,20-*Q ,".*-22#"T

TF1/MIG Cell Line Growth Assay

1VS!-.V#6.0#11',%!#**15#0#0#20-4'0 **720 ,1"3!#"2-#6.0#116:

1UV:>Q1UV>ZUWGQ-0(. 1GXRR 1"#1!0' #" -4#TVZ&-301.-12V',$#!2'-,Q

<1!&!#**15#0#1-02#"-, (>1 ) .: ::(> ,"#/3'4 *#,2!#**,3+ #015#0#

.* 2#"',SR$.!6:13..*#+#,2#"5'2&T,% +&<6V)1T#**15#0#!-3,2#" 1

',"'! 2#"',20'.*'! 2# 7207. , *3##6!*31'-,T&#+#"'3+ ,"&<6V)15 1

0#.* !#" 1,#!#11 07 ,"!#**.-.3* 2'-,15#0#+ ',2 ',#"', ,#6.-,#,2' *

%0-52&.& 1#T<1!V.-1'2'4'27 ,".&-1.&-V.35#0#+-,'2-0#"" '*7 7$*-5

!72-+#207T<0-52&!304#15#0#%#,#0 2#" 7+3*2'.*7',%2&#!#**!-3,2 7.#0!#,2

<1!V.-1'2'4'27T

REFERENCES ST <-00#6Q6-& ++#"6Q**5--"3Q;13-Q! /3#22#.Q. -!-Q#2 *T*','! * 0#1'12 ,!#2-):VWYS! ,!#02� .7! 31#" 7(.V (%#,#+32 2'-,-0 +.*'$'! 2'-,T)!'#,!#TTRRSRT[USZYXVZRT TT >03)#0(Q) 57#01Q3 ,2 0(' ,;Q.#12 >Q.##1#)1Q1-0"6Q#2 *T !2'4'27-$ 1.#!'$'!',&' '2-0-$2&#(.V (270-1',#)', 1#',2&# * 12!0'1'1-$

!&0-,'!+7#*-'"*#3)#+' ," !32#*7+.&- * 12'!*#3)#+' 5'2&2&#!&'* "#*.&' !&0-+-1-+#T-,%*6#"TTRRSRUVVSSRUZVVTT UT )& 0+ )GQ< (-5,'!8#)!QB 7:!Q##>#Q' ,%Q#38 #Q#2 *T !-++-, 1'%, *',%! 1! "#+ 73,"#0*'# ""'!2'-,2-2&#)0!Q(.V (Q ,"<10#!#.2-0 -,!-%#,#1T ,!#0#**TTRRXRSRSVTWVUWT VT 1* đ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�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� .#32'!2 0%#2',&3+ , !32#+7#*-'"*#3) #+' T - 230#TVZWSTXRVUT URT ;3 ,%" BQ)�+ ,(Q#+.'!)'. T)712#+ 2'! ,"',2#%0 2'4# , *71'1 -$* 0%#%#,#*'12131',%> G:> '-',$-0+ 2'!10#1-30!#1T- 2!0-2-!TTRR[RVSVVVWYT UST ;3 ,%" BQ)�+ ,(Q#+.'!)'. T('-',$-0+ 2'!1#,0'!&+#,22--*1S . 2&12-5 0"2&#!-+.0#&#,1'4#$3,!2'-, * , *71'1-$* 0%#%#,#*'121T-3!*#'! !'"1.#1TTRR[RUYSSVSUT

UTT )-,,'!&1#,Q.#',& 0"(6Q'.& 0"2Q *'4'1 2-1 !T +-*#!3* 003*#0 1#"-,.* 1+-,!-3.*',%-$1',%*#%-*" ,"1'*4#0, ,-. 02'!*#1T- 2('-2#!&,-*T TRRWRTUSYVSVWT UUT .#',& 0"(6Q)'36Q % 05 *;Q *'4'1 2-1 !Q'.& 0"2T *' 0 2'-,-$ "7, +'!+-*#!3* 003*#01 1#"-,.* 1+-,!-3.*',% #25##,%-*", ,-. 02'!*#1T - ,-#22TTRRWRWSTTVXVWTT FIGURE LEGENDS

Figure 1. Transient Exposure of CML Cell Lines to Dasatinib Results in Durable

Dephosphorylation of Select Tyrosine Residues in Myeloid Growth-Factor

Receptor Signaling Pathways.

A.)!&#+ 2'!-$): V 1#"/3 ,2'2 2'4#.&-1.&-.0-2#-+'! , *71'1-$%*- *

.&-1.&-270-1',#1'%, *',%',2WXT!#**1 #$-0# ," $2#0 &'%&V"-1#.3*1#

;>!-$" 1 2',' T3WXT!#**1%0-5,',b*'%&2c,-,V'1-2-.#V!-,2 ',',%.!6:5#0#

20# 2#"5'2& SRR,6" 1 2',' $-0TR+',32#1Q ,"!#***71 2#15#0#%#,#0 2#"

#$-0#;>!!.Q 22'+#-$"03%5 1&-32 Q ,"U&0 ,"X&01.-12V;>!

;>!UQ;>!XT/3'4 *#,2*71 2#15#0#%#,#0 2#"$0-+3WXT!#**1%0-5,',b&# 47c

'1-2-.#V!-,2 ',',%.!6:T'%&2 ,"&# 473WXT!#***71 2#15#0#+'6#" 2 SSS

0 2'-.0'-02-.&-1.&-270-1',#.#.2'"#!#SRR#,0'!&+#,2Q.#.2'"#$0 !2'-, 2'-,Q

,"6) 6) , *71'1T

B. ;# 2+ .0#.0#1#,2 2'-,-$.#01'12#,2.&-1.&-07* 2'-,!& ,%#1',+7#*-'"

%0-52&$ !2-00#!#.2-01'%, *',%. 2&5 71'"#,2'$'#" 7 '-',$-0+ 2'!$3,!2'-, *

, *71'1T& ,%#',.&-1.&-07* 2'-, 2# !&;>!2'+#.-',25 1,-0+ *'8#"2-2&#

b!.c!-,"'2'-, ," 0#0#.0#1#,2#"-, *-%TV20 ,1$-0+#"1! *#T<0 7 0# 1

"#1'%, 2#b,-" 2 cT

C.B#12#0,'++3,- *-2 , *71'1-$1#*#!2+7#*-'"%0-52&$ !2-00#!#.2-01'%, *',%

. 2&5 71',3WXT ,"37ZST!#**1 #$-0# ," $2#0 SRR,6;>!-$" 1 2',' T

D.;# 2+ .0#.0#1#,2 2'-,-$(.V (.&-1.&-07* 2'-,'"#,2'$'#" 7

.&-1.&-.0-2#-+'! , *71'1 ,"5#12#0,'++3,- *-2 , *71'1',3WXT!#**1 #$-0#

," $2#0 SRR,6;>!-$" 1 2',' T (S ,3+ #0',%T

Figure 2. BCR-ABL Kinase Activity Rewires GM-CSF Receptor Signaling and

Confers Oncogene Addiction in TF1 Cells.

A.!#0!#,2!*# 4#"! 1. 1#VU,#% 2'4#.-.3* 2'-,*'4#!#**1-$1S .30- ,"

1S (.V (!#**1$-**-5',%VZ&-301-$20# 2+#,25'2&QRTT$>6) QT,% +

&<6V)1QSRR,6" 1 2',' -0SRR,6" 1 2',' 13..*#+#,2#"5'2&T,% +-$&<6V

)1T !2'4#! 1. 1#VU5 1+# 130#" 7$*-5!72-+#207T> 2 0#.0#1#,2 4#0 %#(

)>,-UR#.0RTRRSR25-V5 7 - G 5'2&(-,$#00-,'.-12V2#121T

B.7..#0S',#"' %0 +0#.0#1#,2 2'-,-$"30 2'-,-$1#03+12 04#Q)', 1#',&' '2-0

20# 2+#,2Q ,"%0-52&V$ !2-012'+3* 2'-,T-5#0SB#12#0,'++3,- *-2 , *71'1-$

&<6V)1V+#"' 2#"SR_12'+3* 2'-, 3T !2'4 2'-,Q. )V<!*- "',%Q ,"

!2'4 2'-,-$"-5,120# +#$$#!2-01$0-+5&-*#!#***71 2#1',1S .30- ,"

1S (.V (!#**120# 2#"$-0S&-305'2&SRR,6" 1 2',' T&# !2'4 2'-,12 231

-$ 3T5 1"#2#0+',#" 7'++3,-.0#!'.'2 2'-, ," !2'4 2'-,*--.

.&-1.&-07* 2'-,#SRRYT. ) !2'4 2'-,5 1+-,'2-0#"31',% . )V<!.3**V

"-5, 11 7T

C.7..#0S',#"' %0 +0#.0#1#,2 2'-,-$"30 2'-,-$1#03+12 04#Q)', 1#',&' '2-0

20# 2+#,2Q ,"%0-52&V$ !2-012'+3* 2'-,T-5#0SB#12#0,'++3,- *-2 , *71'1-$

&<6V)1V+#"' 2#"SR_12'+3* 2'-,. )V<!*- "',% ," !2'4 2'-,-$

"-5,120# +#$$#!2-01',1S .30- ,"1S (.V (!#**1 $2#01&-02V2#0+ ,"

#62#,"#"" 1 2',' 20# 2+#,2SRR,6SS&0QT&01QV&01QZ&01T. ) !2'4'275 1

+-,'2-0#" 1',(T

D.--0+ *'8#". )V<!*- "',%',&<6V)1V12'+3* 2#"SR_1S .30- ,"

1S (.V (!#**1 $2#0.0-*-,%#"" 1 2',' 20# 2+#,2SRR,6QTV&01T. )

!2'4'275 1+-,'2-0#" 1',(T. )V<!*- "',%5 1,-0+ *'8#"2-2&#*#4#*

- 1#04#"',2&#b1S .30-V>6) &&<6V)1c!-,"'2'-,$-0# !.#0'+#,2 *

0#.*'! 2#T> 2 0#.0#1#,22&# 4#0 %#&)>,-UR##.0RTRSR25-V5 7 - G 5'2&

(-,$#00-,'.-12V2#121T

E.7..#0S',#"' %0 +0#.0#1#,2 2'-,-$"30 2'-,-$1#03+12 04#Q)', 1#',&' '2-0

20# 2+#,2Q ,"%0-52&V$ !2-012'+3* 2'-,T-5#0SB#12#0,'++3,- *-2 , *71'1-$

5&-*#!#***71 2#1$0-+1S .30- ,"1S (.V (!#**1 $2#0.0-*-,%#"" 1 2','

20# 2+#,2SRR,6QTV&01 ,"&<6V)112'+3* 2'-,SR_T

Figure 3. Erythropoietin Receptor-Mediated Activation of the JAK2/STAT5,

RAS/MAPK, and PI3K/AKT Signaling Pathways is Attenuated by BCR-ABL

Kinase Activity in K562 Cells.

A.--0+ *'8#"&! V+#"' 2#"SR_12'+3* 2'-, 3T !2'4 2'-,',3WXT!#**1

20# 2#"$-0S&05'2&#'2�SRR,6" 1 2',' -0Sμ6'+ 2',' T> 2 0#.0#1#,212&#

4#0 %#()>,-UT 3T !2'4 2'-,5 1+-,'2-0#" 7'++3,-.0#!'.'2 2'-, ,"

!2'4 2'-,*--.#SRRY.&-1.&-07* 2'-,T 3T !2'4 2'-,5 1,-0+ *'8#"2-2&#

*#4#*-$.&-1.&-V#SRRY- 1#04#"',2&#b>6) c!-,"'2'-,$-0# !.#0'+#,2 *

0#.*'! 2#T

B.7..#0S',#"' %0 +0#.0#1#,2 2'-,-$"30 2'-,-$1#03+12 04#Q)', 1#',&' '2-0

20# 2+#,2Q ,"%0-52&V$ !2-012'+3* 2'-,T-5#0SB#12#0,'++3,- *-2 , *71'1-$

5&-*#!#***71 2#1$0-+3WXT!#**1 $2#01&-02V2#0+ ,".0-*-,%#"(.V (

',&' '2'-,SRR,6" 1 2',' ST&01QV&01QZ&01QTV&01RRTT$>6) QTV&01$-**-5#"

7&! 12'+3* 2'-,SR_T

C.--0+ *'8#"&! V+#"' 2#" 3T !2'4 2'-,',3WXT!#**1 $2#01&-02V2#0+S&0

,".0-*-,%#"TV&01SRR,6" 1 2',' 20# 2+#,2$-**-5#"&! 12'+3* 2'-,SR_T

> 2 '10#.0#1#,2 2'4#-$20'.*'! 2##6.#0'+#,2 * , *71'1T 3T !2'4 2'-, ,"

,-0+ *'8 2'-,5 1.#0$-0+#" 1', T

D.--0+ *'8#". )V<!*- "',%',3WXT!#**1 $2#01&-02V2#0+S&0 ,".0-*-,%#"

TV&01SRR,6" 1 2',' 20# 2+#,2$-**-5#" 7&! 12'+3* 2'-,SR_T> 2 '1

0#.0#1#,2 2'4#-$20'.*'! 2##6.#0'+#,2 * , *71'1T. ) !2'4 2'-,5 1+-,'2-0#"

31',% . )V<!.3**"-5, 11 7 ,". )V<!*#4#*15#0#,-0+ *'8#"2-2&#b>6) c

!-,"'2'-,T

E.--0+ *'8#"&! V+#"' 2#"SR_12'+3* 2'-, 3T !2'4 2'-,',3WXT!#**1

.0#20# 2#"$-0TV&015'2&RTT$>6) QSRR,6" 1 2',' QSμ6'+ 2',' QWRR,6

+-,'2-0#" ,",-0+ *'8#" 1', T

F.7..#0S',#"' %0 +0#.0#1#,2 2'-,-$"30 2'-,-$1#03+12 04#Q)', 1#',&' '2-0

20# 2+#,2Q ,"%0-52&V$ !2-012'+3* 2'-,T-5#0SB#12#0,'++3,- *-2 , *71'1-$

5&-*#!#***71 2#1',3WXT!#**1.0#20# 2#"$-0TV&015'2&RTT$>6) QSRR,6

" 1 2',' QSμ6'+ 2',' QWRR,6

'+ 2','

Figure 4. Global Gene Expression Analysis of Dasatinib Treated K562 Cells

Identifies Candidate Mediators Responsible for the Attenuation of Myeloid GF-

R Signaling in CML Cells.

A.;# 2+ .0#.0#1#,2 2'-,-$2&#SXT%#,#11'%,'$'! ,2*7"-5,V0#%3* 2#" $2#0VQZQ

,"TV&-301-$" 1 2',' 20# 2+#,2',3WXT!#**1T;# 2+ .',1#22-2�'%&2

&'%&*'%&21%#,#15'2&',2&'1%0-3.2& 2 0# 11-!' 2#"5'2&,#% 2'4#$##" !)-$2&#

. ) 6 !3 ," 3 ) 1'%, *',%. 2&5 71Q 15#** 12 ,1!0'.2'-, *-32.32

-$.3T&#!-*3+,2-2&#*#$2"#,-2#1%#,#1.0#4'-31*70#.-02#"2- #',4-*4#"',

2&#,#% 2'4#$##" !),#25-0)-$(. 1GXRR#6.0#11',%!#**1XQTWT&#&# 2

+ . 22&# -22-+&'%&*'%&21 $#5-$2&#%#,#15'2&',!0# 1#"#6.0#11'-,$-**-5',%

" 1 2',' 20# 2+#,2',3WXT!#**1T

B.A3 ,2'2 2'4#!./!. , *71'1-$.-2#,2' *,#% 2'4#$##" !)%#,#1',3WXT

!#**120# 2#"5'2&" 1 2',' SRR,6Q'+ 2',' Sμ6Q-0!>RUTW[RSWRR,6T&#

V++2 4#0 %#$-*"#6.0#11'-,!& ,%#T ,"12 ," 0""#4' 2'-,)>$-*"V!& ,%#$-0

# !&%#,#'10#.0#1#,2#",-UT

C.7..#0S',#"' %0 +0#.0#1#,2 2'-,-$"30 2'-,-$1#03+12 04#Q)', 1#',&' '2-0

20# 2+#,2Q ,"%0-52&V$ !2-012'+3* 2'-,T-5#0SB#12#0,'++3,- *-2 , *71'1-$

. ) ,".3 !2'4'27 #$-0# ," $2#0&! V12'+3* 2'-,SR_',3WXT!#**1

.0#20# 2#"$-0TV&015'2&RTT$>6) QSRR,6" 1 2',' QWRR,6!>RUTW[RSQ-0

" 1 2',' !>RUTW[RST. ) !2'4'275 1+-,'2-0#"31',% . )V<!.3**"-5,

11 7T

D.7..#0S',#"' %0 +0#.0#1#,2 2'-,-$"30 2'-,-$1#03+12 04#Q)', 1#',&' '2-0

20# 2+#,2Q ,"%0-52&V$ !2-012'+3* 2'-,T-5#0SB#12#0,'++3,- *-2 , *71'1-$

3T ,") W !2'4'27 #$-0# ," $2#0&! V12'+3* 2'-,',3WXT!#**120# 2#"

3,"#02 +##6.#0'+#,2 *!-,"'2'-,1 1 T 3T !2'4 2'-,5 1"#2#0+',#" 7

'++3,-.0#!'.'2 2'-, ," !2'4 2'-,*--.#SRRY.&-1.&-07* 2'-,T

Figure 5. Caspase-3 Activity is Detected in Dasatinib Treated K562 Cells Prior

to Complete Relief of Negative Feedback.

A. B#12#0,'++3,- *-2 11#11+#,2-$!*# 4#"! 1. 1#VU',5&-*#!#***71 2#1$0-+

3WXT!#**120# 2#"5'2&SRR,6" 1 2',' $-0V&01QZ&01QST&01Q ,"TV&01T

B. .#.0#1#,2 2'-,-$ 1',%*#%-*", ,-1#,1-0',2#,1'2720 !# 1 $3,!2'-,-$2'+#T

:,2 !2, ,-1#,1-07'#*"1 &'%&1! 22#0',%',2#,1'27Q5&'*#!322',%#4#,2+#"' 2#" 7

! 1. 1#VU'1- 1#04#" 1 ,',2#,1'27"0-."3#2-*-11',.* 1+-,!-3.*',%TSQUTQ

UUT

C..#.0#1#,2 2'4#" 0)$'#*"'+ %#1-$, ,-1#,1-01 #$-0# ," $2#0#6.-130#2-!#**

*71 2#1$0-+3WXT!#**120# 2#"5'2&4#&'!*#>6) -0SRR,6" 1 2',' T

D.-2 *,-0+ *'8#", ,-1#,1-0!322',%#4#,21- 1#04#"',3WXT!#***71 2#120# 2#"

5'2&4#&'!*#>6) ,"SRR,6" 1 2',' T0# 2+#,2-$*71 2#15'2&2&#! 1. 1#VU

',&' '2-08V>G>V!+)'11&-5, 1 !-,20-*T

Figure 6. BCR-ABL-Dependent Negative Feedback Differs from BRAFV600E,

FLT3-ITD, and FLT3-D835V in TF1 Cells

A. <0-52&!304#1-$1S<1!V.-1'2'4#!#**1#6.0#11',%(.V (Q(. 1GXRRQ1UV

:>Q-01UV>ZUWGT#**%0-52&',2&#.0#1#,!#-$T,% +&<6V)15 1

+-,'2-0#"$-0SU" 71T> 2 0#.0#1#,212&# 4#0 %#()>,-UR#.0RTRRS$-0.TSR

41T1UV:> ,"1UV>ZUWG-," 7SUQ##.0RTRRS$-06:<41T **-2�!#***',#1

-," 7SUT5-V5 7 - G 5'2&(-,$#00-,'.-12V2#121T

B. !#0!#,2!*# 4#"! 1. 1#VU,#% 2'4#.-.3* 2'-,*'4#!#**1-$1S .30- ,"

1S 1UV:>!#**1$-**-5',%VZ&-301-$20# 2+#,25'2&T,% +&<6V)1QSR,6

TTRQRTT$>6) Q-0SR,6 TTR13..*#+#,2#"5'2&T,% +-$&<6V)1T

!2'4#! 1. 1#VU5 1+# 130#" 7$*-5!72-+#207T> 2 0#.0#1#,2 4#0 %#()>

,-US#.0RTRRSR25-V5 7 - G 5'2&(-,$#00-,'.-12V2#121T

C. B#12#0,'++3,- *-2 , *71'1-$1S .30- ,"1S 1UV:>5&-*#!#***71 2#1

$-**-5',%.0-*-,%#"1UV:>',&' '2'-,SR,6 TTRST&01QV&01QZ&01QTV&01R

RTT$>6) QTV&-301 ,"&<6V)112'+3* 2'-,SR_T

Figure 7. Model of BCR-ABL-Mediated Oncogene Addiction

A.)!&#+ 2'!0#.0#1#,2 2'-,-$(.V (V+#"' 2#"-,!-%#,# ""'!2'-,T(.V (

#6.0#11',%!#**1','2' 2# ,"!-++'22- .-.2-1'1.0'-02-2&#!-+.*#2#0#*'#$-$

63V"#.#,"#,2,#% 2'4#$##" !) 22&#*#4#*-$<1V.1'%, *',%T

B.)!&#+ 2'!!-+. 0'1-,-$2&#)',#2'!1-$ .-.2-1'1',"3!2'-,0#"" 1&#"*',#

,"*-11-$,#% 2'4#$##" !)',(. 1GXRRV#6.0#11',%+#* ,-+ !#**1!7 ,1-*'"

*',# ,"(.V (V#6.0#11',%6!#**1 *3#1-*'"*',#T

Downloaded from '(!

Author manuscriptshavebeenpeerreviewedandacceptedforpublicationbutnotyetedited. Author ManuscriptPublishedOnlineFirstonDecember20,2013;DOI:10.1158/2159-8290.CD-13-0235 !&! !95$% 7 6

# ' cancerdiscovery.aacrjournals.org ( 2 2 2 2 2 # ' 2 2 (2 (2 (2 (2 $1 '(!

!&! '(! !97$% # '

!&!

Research. # ' 09B38) )) @ ) 09B38$0 ) @ $0 09B38!($ 0 2 @ !($ 09B38)00 22 @ )00 !# $# ! " " " " %

# ' " ( 09B38 2 @ 4 2 @ 4 2 @ 4 2 @ 4 2 @ ( Author Manuscript Published OnlineFirst on December 20, 2013; DOI: 10.1158/2159-8290.CD-13-0235 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.

MEK-Dependent Negative Feedback Underlies BCR-ABL-Mediated Oncogene Addiction

Jennifer Asmussen, Elisabeth A Lasater, Cheryl Tajon, et al.

Cancer Discovery Published OnlineFirst December 20, 2013.

Updated version Access the most recent version of this article at: doi:10.1158/2159-8290.CD-13-0235

Supplementary Access the most recent supplemental material at: Material http://cancerdiscovery.aacrjournals.org/content/suppl/2013/12/19/2159-8290.CD-13-0235.DC1 http://cancerdiscovery.aacrjournals.org/content/suppl/2021/03/02/2159-8290.CD-13-0235.DC2

Author Author manuscripts have been peer reviewed and accepted for publication but have not yet been Manuscript edited.

E-mail alerts Sign up to receive free email-alerts related to this article or journal.

Reprints and To order reprints of this article or to subscribe to the journal, contact the AACR Publications Subscriptions Department at [email protected].

Permissions To request permission to re-use all or part of this article, use this link http://cancerdiscovery.aacrjournals.org/content/early/2013/12/20/2159-8290.CD-13-0235. Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.